Centessa Pharmaceuticals (NASDAQ:CNTA) Coverage Initiated at BMO Capital Markets

Equities research analysts at BMO Capital Markets initiated coverage on shares of Centessa Pharmaceuticals (NASDAQ:CNTAGet Rating) in a research note issued to investors on Thursday, The Fly reports. The firm set an “outperform” rating on the stock.

Other equities research analysts have also recently issued reports about the company. Morgan Stanley dropped their price objective on Centessa Pharmaceuticals from $19.00 to $15.00 and set an “overweight” rating for the company in a research note on Tuesday, May 24th. The Goldman Sachs Group decreased their target price on Centessa Pharmaceuticals from $12.00 to $8.00 and set a “neutral” rating for the company in a report on Tuesday, May 24th. Finally, Jefferies Financial Group lowered Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $4.00 target price for the company. in a report on Friday, June 3rd.

Shares of NASDAQ CNTA traded down $0.14 during trading on Thursday, reaching $4.12. The stock had a trading volume of 3,272 shares, compared to its average volume of 248,020. Centessa Pharmaceuticals has a fifty-two week low of $2.88 and a fifty-two week high of $26.90. The company has a debt-to-equity ratio of 0.16, a quick ratio of 21.37 and a current ratio of 21.37. The business’s 50-day moving average price is $6.48 and its 200-day moving average price is $8.72. The company has a market cap of $387.45 million and a P/E ratio of -1.73.

Centessa Pharmaceuticals (NASDAQ:CNTAGet Rating) last issued its quarterly earnings data on Monday, May 16th. The company reported ($0.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.09. Analysts forecast that Centessa Pharmaceuticals will post -2.18 EPS for the current fiscal year.

In other Centessa Pharmaceuticals news, EVP Antoine Yver sold 20,222 shares of Centessa Pharmaceuticals stock in a transaction dated Tuesday, May 17th. The stock was sold at an average price of $5.42, for a total transaction of $109,603.24. Following the completion of the sale, the executive vice president now directly owns 813,675 shares of the company’s stock, valued at approximately $4,410,118.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 9.09% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of America Corp DE purchased a new stake in shares of Centessa Pharmaceuticals in the 2nd quarter valued at about $54,000. Morgan Stanley purchased a new stake in shares of Centessa Pharmaceuticals in the 3rd quarter valued at about $128,000. Point72 Asset Management L.P. lifted its holdings in shares of Centessa Pharmaceuticals by 202.2% in the 3rd quarter. Point72 Asset Management L.P. now owns 302,200 shares of the company’s stock valued at $5,047,000 after purchasing an additional 202,200 shares during the last quarter. Brookfield Asset Management Inc. lifted its holdings in shares of Centessa Pharmaceuticals by 45.6% in the 3rd quarter. Brookfield Asset Management Inc. now owns 26,788 shares of the company’s stock valued at $447,000 after purchasing an additional 8,384 shares during the last quarter. Finally, Medicxi Ventures Management Jersey Ltd lifted its holdings in shares of Centessa Pharmaceuticals by 1.1% in the 4th quarter. Medicxi Ventures Management Jersey Ltd now owns 18,123,892 shares of the company’s stock valued at $204,075,000 after purchasing an additional 200,000 shares during the last quarter. 95.72% of the stock is owned by institutional investors.

About Centessa Pharmaceuticals (Get Rating)

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B.

Featured Stories

The Fly logo

Want More Great Investing Ideas?

Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.